Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform

BMC Cancer

Table 4 Robustness checks on changes in initiation of AET after state health reform in low-income areas vs. high-income area

	(1)	(2)	(3)
	Breast cancer patients who are both ER and PR positive	Excluding patients with in situ disease at diagnosis¹	Adjusting for county-level controls²
Breast cancer patients aged 20–64 years	0.038***	0.049***	0.051***
Breast cancer patients aged 20–64 years	[0.106, 0.065]	[0.021, 0.076]	[0.025, 0.077]
N	17,725	15,543	20,551
Breast cancer patients aged 20–49 years	0.056**	0.087***	0.068***
Breast cancer patients aged 20–49 years	[0.012, 0.100]	[0.040, 0.133]	[0.026, 0.110]
N	7110	5801	7960
Breast cancer patients aged 50–64 years	0.025	0.026	0.040**
Breast cancer patients aged 50–64 years	[−0.009, 0.060]	[−0.009, 0.061]	[0.007, 0.072]
N	10,615	9652	12,591

These robustness checks were conducted in the main multivariable difference-in-differences regressions in Table 2, which controls for age at diagnosis, marital status, race/ethnicity, stage at diagnosis, and type of surgery
AET Adjuvant Endocrine Therapy, ER Estrogen Receptor, PR Progesterone receptor
***p-value< 0.01 **p-value< 0.05
^aDerived American Joint Committee on Cancer (AJCC) stage = 0
^bMedian household income, percent unemployed, percent with less than a high school education, percent non-Hispanic white, percent urban; and primary care physicians, specialist physicians, safety net provider, and hospital beds all specified as rate per 1000 population

ISSN: 1471-2407